Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) - Trial NCT05934526
Access comprehensive clinical trial information for NCT05934526 through Pure Global AI's free database. This Phase 3 trial is sponsored by GB002, Inc. and is currently Not yet recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 350 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
GB002, Inc.
Gossamer Bio Inc.
Timeline & Enrollment
Phase 3
Sep 30, 2023
Oct 01, 2025
Primary Outcome
Change in distance achieved on the six-minute walk test (6MWT), six-minute walk distance (ฮ6MWD) from baseline to Week 24
Summary
The primary objective of the study is to determine the effect of seralutinib on improving
 exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary
 objective for this trial is to determine time to clinical worsening.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05934526
Non-Device Trial